Amgen Stemgen
Executive Summary
FDA Biological Response Modifiers Advisory Committee will review BLA 97-0509 for Stemgen (ancestim) in combination with Amgen's Neupogen (filgrastim) for mobilization of peripheral blood progenitor cells on July 30. The committee will also discuss the report from the Dec. 17 meeting of the Xenotransplantation Subcommittee and the research programs in the Center for Biologics Evaluation & Research's Laboratory of Immunology and Laboratory of Molecular Immunology. The meeting will be at the Holiday Inn in Bethesda, Md. at 8 a.m...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth